Aquestive Therapeutics, Inc. · NASDAQ:AQST

Aquestive Therapeutics — Q3 2026 Earnings Presentation

13 slides from Aquestive Therapeutics's earnings presentation, Nov 3, 2026

  1. Slide 1: Third Quarter 2026 Earnings Supplemental Materials

    Third Quarter 2026 Earnings Supplemental Materials November 3, 2026

  2. Slide 2: Disclaimer

    © 2026 Aquestive Therapeutics, Inc. Disclaimer 2 These forward-looking statements include, but are not limited to, statements regarding the advancement and related timing of Anaphylm (dibutepinephrine) Sublingual Film through the FDA regulatory review and approval process; our ability to address the

  3. Slide 3: Q3 2026 Earnings Key Messages

    Q3 2026 Earnings Key Messages Anaphylm (dibutepinephrine) sublingual film for severe allergic reactions, including anaphylaxis • Anaphylm New Drug Application (NDA) was resubmitted in Q3 2026 • PDUFA goal date is March 16, 2027 • Commercial launch preparations remain on track for a potential launch

  4. Slide 4: Lead Asset Anaphylm (dibutepinephrine) sublingual film

    Lead Asset Anaphylm (dibutepinephrine) sublingual film 4 ANAPHYLM (dibutepinephrine) sublingual film is an investigational product candidate that has not been approved by the U.S. Food and Drug Administration. Safety and efficacy have not been established. Statements regarding potential benefits, cl

  5. Slide 5: Market Insights Inform Anaphylm Launch Planning

    5  Build allergist awareness and confidence through scientific exchange and education  Communicate Anaphylm’s potential product differentiation, if approved  Incorporate patient and caregiver insights into education and support  Simplify access, fulfillment and patient support  Engage payers re

  6. Slide 6: Broad Scientific and Prescriber Engagement Builds Anaphylm Awareness

    6 50 Conferences Attended & Planned 876+ Booth Engagements 1090+ Prescriber interactions 14 Manuscripts drafted 10 Conference abstracts submitted Broad Scientific and Prescriber Engagement Builds Anaphylm Awareness¹ 1. Year-to-date information.

  7. Slide 7: 96% of Survey Respondents Preferred Film in a Hands-on Preference Survey

    96% of Survey Respondents Preferred Film in a Hands-on Preference Survey¹,² 51 1 1 PREFER FILM PREFER FILM & NASAL EQUALLY PREFER NASAL Survey Results 1. Aquestive Therapeutics data on file. 2. Survey results reflect stated respondent preferences under controlled survey conditions and should not be

  8. Slide 8: Upcoming Milestones and Third Quarter 2026 Results

    Upcoming Milestones and Third Quarter 2026 Results 8

  9. Slide 9: Recently Completed & Expected Key Milestones

    Recently Completed & Expected Key Milestones 9 Q2 2027Q1 2027Q4 2026Q3 2026 NDA Resubmitted PDUFA Goal Date March 16th Anaphylm Launch, if approved by FDAAnaphylm Additional Clinical StudiesAQST-108 Libervant PDUFA Goal Dates in March Ex-US Filing in Canada

  10. Slide 10: Cash Management Remains On Track

    Cash Management Remains On Track 10 $121.2 $110.7 $98.5 $90.3 0 20 40 60 80 100 120 Q4 25 Q1 26 Q2 26 Q3 26 U SD (M illi on s) Ending Cash Balance by Quarter

  11. Slide 11: Quarterly Manufacturing Shipment Volumes

    Quarterly Manufacturing Shipment Volumes 11 45,328 42,516 34,418 43,838 43,032 27,262 37,204 43,801 47,250 33,320 47,909 25,831 0 10,000 20,000 30,000 40,000 50,000 60,000 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 D O SE S SH IP PE D (0 00 ’S ) QUARTER Doses Shipped by

  12. Slide 12: 2026 Guidance as of November 3, 2026

    2026 Guidance as of November 3, 2026 12 2026 Outlook • Total revenues of approximately $46-$50 million • Non-GAAP adjusted EBITDA loss of approximately $35-$30 million

  13. Slide 13: Thank You

    Thank You 13

Aquestive Therapeutics — Q3 2026 Earnings Presentation on 6ix